Option Care Health, Inc. (NASDAQ:OPCH) Stock Holdings Lessened by Retirement Systems of Alabama

Retirement Systems of Alabama trimmed its stake in Option Care Health, Inc. (NASDAQ:OPCH) by 0.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 206,926 shares of the company’s stock after selling 827 shares during the quarter. Retirement Systems of Alabama owned 0.12% of Option Care Health worth $4,801,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in the stock. Jennison Associates LLC lifted its position in shares of Option Care Health by 4.5% in the fourth quarter. Jennison Associates LLC now owns 493,363 shares of the company’s stock worth $11,446,000 after purchasing an additional 21,089 shares in the last quarter. Highland Capital Management LLC purchased a new stake in shares of Option Care Health in the fourth quarter worth approximately $238,000. Pacer Advisors Inc. lifted its position in shares of Option Care Health by 2.2% in the fourth quarter. Pacer Advisors Inc. now owns 25,483 shares of the company’s stock worth $591,000 after purchasing an additional 537 shares in the last quarter. KBC Group NV lifted its position in shares of Option Care Health by 46.4% in the fourth quarter. KBC Group NV now owns 7,337 shares of the company’s stock worth $170,000 after purchasing an additional 2,324 shares in the last quarter. Finally, Blue Trust Inc. lifted its position in shares of Option Care Health by 16.9% in the fourth quarter. Blue Trust Inc. now owns 4,703 shares of the company’s stock worth $109,000 after purchasing an additional 681 shares in the last quarter. 98.05% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on OPCH shares. Truist Financial dropped their price objective on Option Care Health from $41.00 to $34.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Bank of America upgraded Option Care Health from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $26.00 to $33.00 in a report on Monday, January 13th. Jefferies Financial Group upgraded Option Care Health from a “hold” rating to a “buy” rating and increased their price objective for the stock from $26.00 to $35.00 in a report on Thursday, January 23rd. UBS Group started coverage on Option Care Health in a report on Thursday, December 5th. They issued a “neutral” rating and a $26.00 price objective on the stock. Finally, The Goldman Sachs Group downgraded Option Care Health from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $38.00 to $27.00 in a report on Monday, November 4th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.25.

Option Care Health Trading Up 1.2 %

Shares of OPCH stock opened at $31.35 on Tuesday. Option Care Health, Inc. has a 12 month low of $21.39 and a 12 month high of $34.63. The company has a quick ratio of 1.32, a current ratio of 1.73 and a debt-to-equity ratio of 0.77. The business’s 50 day moving average is $26.04 and its two-hundred day moving average is $27.87. The company has a market cap of $5.34 billion, a PE ratio of 26.34, a price-to-earnings-growth ratio of 2.19 and a beta of 1.35.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.